Development of biosimilars in an era of oncologic drug shortagesEdward Li, Scott Anderson, Janakiraman Subramanian et al.|Drug Design Development and Therapy|2015Cited by 41
Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non–Small-Cell Lung CancerSuresh S. Ramalingam, Fadlo R. Khuri, Nabil F. Saba et al.|Journal of Thoracic Oncology|2013Cited by 39
Clinical response rate at primary tumor site (PTS) following a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (<i>nab</i>-)paclitaxel and cetuximab with every-3-week cisplatin and 5-FU (ACCF) versus docetaxel, cisplatin, 5-FU, and cetuximab (TPF + C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).Douglas R. Adkins, D. I. Kuperman, Jessica Ley et al.|Journal of Clinical Oncology|2011Cited by 6
Clinical response rate at primary tumor site by WHO criteria following an induction chemotherapy regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every 3 week cisplatin and 5-FU in patients with locally advanced nonmetastatic head and neck squamous cell carcinoma (HNSCC).D. I. Kuperman, Douglas R. Adkins, Jessica Ley et al.|Journal of Clinical Oncology|2010Cited by 2